Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Prelude Therapeutics logo — Precision Oncology, Redefined.

Prelude Therapeutics

Precision Oncology, Redefined.

Founded 2016 United States Wilmington, United States 126 employees Post-IPO Equity Total: $147.00M Biopharma, Biotechnology +2

General Information

Company Name Prelude Therapeutics
Founded Year 2016
Location United States Wilmington, United States
Founders / Decision Makers
Team member
Employees 126
Industries Biopharma, Biotechnology, Health and Wellness +1
Funding Stage Post-IPO Equity
Business Model B2B, B2D
Revenue Model Licensing, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with Prelude Therapeutics. To contact Prelude Therapeutics, visit preludetx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Prelude Therapeutics compare?

A PDF of Prelude Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Prelude Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Prelude Therapeutics

Prelude Therapeutics, founded in 2016, is a United States-based clinical-stage precision oncology company redefining cancer treatment with a focus on developing innovative drug candidates that target critical cancer cell pathways. The company uniquely positions itself within the Biopharma, Biotechnology, Health and Wellness, and Pharmaceutical industries.

The company's diverse pipeline is notably distinguished by proprietary small molecule compounds designed to target clinically validated pathways for cancers affecting underserved patient populations. Currently, Prelude Therapeutics has three candidates in clinical development: PRT3789, a highly selective SMARCA2 degrader; PRT2527, a potent CDK9 inhibitor; and PRT3645, a next-generation CDK4/6 inhibitor, alongside a preclinical oral candidate targeting SMARCA2.

Their most recent financial milestone was a $25.00M Post-IPO Equity investment on 11 December 2023, underscoring investor confidence in their potential to revolutionize precision oncology.

Business keywords: Precision Oncology, Clinical-stage, Cancer Therapeutics, Small Molecule Compounds, Targeted Cancer Pathways, SMARCA2 Degrader, CDK9 Inhibitor, CDK4/6 Inhibitor, Cancer Resistance Mechanisms, Oncology Drug Development, Orally Bioavailable Therapies, Novel Cancer Therapies, Healthcare Innovation, Cancer Research

Services & Products

Development of precision oncology medicines
Innovative cancer drug discovery
Targeted protein degradation technology
Pipeline of clinical and preclinical programs

Target Customers

Cancer Patients Oncologists Healthcare Providers Pharmaceutical Partners

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $25.00M -
11 Dec 2023
Series C $50.00M 2
OrbiMed Fidelity
OrbiMed, Fidelity
24 Aug 2020
Series B $60.00M 1
OrbiMed
OrbiMed
12 Jun 2019
Venture Round $12.00M -
20 Oct 2017

Prelude Therapeutics Alternatives & Competitors

View All Alternatives
Prelude Therapeutics vs
Redx Pharma
Redx Pharma United Kingdom

Biotech company focusing on the discovery and development of novel targeted medicines to treat cance...

Post-IPO Equity
39 employees
Biotechnology, Health Care
Prelude Therapeutics vs
Treadwell Therapeutics, Inc.
Treadwell Therapeutics, Inc. United States

The Path to Better

Series B
14 employees
Biotechnology, Health Care
Compare Prelude Therapeutics vs Treadwell Therapeutics, Inc.
Prelude Therapeutics vs
Cybrexa Therapeutics
Cybrexa Therapeutics United States

Changing the paradigm for cancer treatment through the development of antigen-independent peptide dr...

Series B
11 employees
Biotechnology, Health and Wellness
Also compare with: Prelude Therapeutics vs iOmx Therapeutics AG iOmx Therapeutics AG Prelude Therapeutics vs Avenzo Therapeutics Avenzo Therapeutics Prelude Therapeutics vs Alterome Therapeutics, Inc Alterome Therapeutics, Inc View all alternatives

FAQ About Prelude Therapeutics

Precision Oncology, Redefined.
Prelude Therapeutics was founded in 2016.
Prelude Therapeutics is headquartered in Wilmington, United States.
Prelude Therapeutics operates in Biopharma, Biotechnology, Health and Wellness and Pharmaceutical. Its work centres on Precision Oncology, Clinical-stage, Cancer Therapeutics and Small Molecule Compounds. Its customers include Cancer Patients, Oncologists and Healthcare Providers.
Prelude Therapeutics has a B2B and B2D business model. Its revenue comes from Licensing and Product Sales.
Prelude Therapeutics has approximately 126 employees.
Prelude Therapeutics has completed 4 funding rounds, raising a total of $147.00M. The latest funding stage is Post-IPO Equity.
Prelude Therapeutics offers: Development of precision oncology medicines, Innovative cancer drug discovery, Targeted protein degradation technology, Pipeline of clinical and preclinical programs.
Top alternatives and competitors to Prelude Therapeutics include Redx Pharma, Treadwell Therapeutics, Inc., Cybrexa Therapeutics, iOmx Therapeutics AG, Afecta Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Prelude Therapeutics and Redx Pharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Prelude Therapeutics, https://bouncewatch.com/company/prelude-therapeutics, updated 27 November 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout